LEAP-BIO

LEAP-BIO is a COSME project which aims to **develop IP licensing intermediary services** for early stage assets in **Pharma** and **BIOtech**.

This document was created to collect information about early-stage assets that match the in-licensing interests we collected from the big pharma and well-funded biotech companies. Please provide only non-confidential information. The matchmaking activities are human-curated, ensuring personalized and accurate matching of licensing interests with early-stage assets. In case there is an expression of interest from a company in your asset, you will be asked to provide us further information (a NDA may be set up at that time, if needed).

If you have any questions, please contact imm-techtransfer@medicina.ulisboa.pt

Title:

Asset description:

Therapeutic area:
Please select the therapeutic area from the pdf 'Interests from big pharma & biotech'

Therapeutic sub-area:
If applicable, please select the therapeutic sub-area from the pdf 'Interests from big pharma & biotech'

Therapeutic indication:
Please select the therapeutic indication from the pdf 'Interests from big pharma & biotech'

Other :
If your therapeutic indication did not appeared in the previous list, please indicate it here

Category:

☐ Drug

☐ Target

☐ Enabling technology

☐ Other, please speficy:

If you selected 'Drug', please specify the therapeutic modality:

☐ Antibody

☐ Small molecule

☐ Gene therapy

☐ Cell therapy

☐ RNA-based therapy

☐ Peptide

☐ Protein

☐ Viral vectors

    DNA-repair inhibitors

Vaccinology

Biologics

Advanced therapy

Toxin

Large mollecules

Antibody-drug conjugates (ADC)

Degraders (PROTACs, Molecular Glues)

Milamolecules

Other, please speficy:

If you selected 'Drug', please select the correct option :

☐ First-in-class

Best-in-class

If you selected 'Target', please select the most suitable option :

If you selected 'Enabling technology', please select the category :

If you selected 'Enabling technology', please select most suitable option :

Target/mechanism of action :

Stage of development:
☐ Target ID
☐ Target validation
☐ *in vitro* PoC
☐ *in vivo* PoC
☐ Hit ID
☐ Hit to lead
☐ Lead optimization
☐ IND-enabling

Please provide an overview of the package of results you have:

LEAP-BIO

IP protection status :

Track record :